期刊文献+

单中心腹膜透析患者SHPT的现况调查及相关因素分析

下载PDF
导出
摘要 目的:调查腹膜透析患者SHPT的发生情况并探讨其相关影响因素。方法对2年来在我院腹透门诊透析治疗的166名患者进行回顾性分析,按透析龄<1年,1~3年,>3年分为3组进行研究。结果所有患者其中合并SHPT的患者有83例,发生率为50%,透析龄<1年组有63例,SHPT患者有32例,发生率为50.79%;透析龄在1~3年组有70例,SHPT患者有33例,发生率为47.14%;透析龄>3年组有33例,SHPT患者有18例,发生率为54.55%。结论①腹膜透析患者的SHPT发生率较高,随着透析时间的延长,PD患者的尿量呈逐渐减少趋势,但SHPT的发生率并无显著性升高。②不同透析龄组间的血压和生化指标无明显差异,但需增加腹膜透析清除率以抵消残肾功能的逐渐丧失。3.PD患者的PTH水平与BUN、CRE、ALB、血P、CO2CP、TG、尿钙排出量、uKt/v、uCcr、TCcr等因素相关,而BUN和尿钙排出量是PTH的独立危险因素。
出处 《医学信息(医学与计算机应用)》 2014年第16期233-234,共2页 Medical Information
  • 相关文献

参考文献2

二级参考文献21

  • 1罗群.终末期肾功能衰竭患者高磷血症治疗进展[J].现代实用医学,2004,16(12):697-698. 被引量:7
  • 2Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol, 2004, 15:2208-2218.
  • 3London GM, Guerin AP, Marchais SJ, et al. Arterial media calcification in end-stage renal disease:impact on all-canse and cardiovascular mortality. Nephrol Dial Transplant,2003,18 : 1731-1740.
  • 4Gal-Moscovici A, Sprague SM. Role of vitamin D deficiency in chronic kidney disease. J Bone Miner Res ,2007 ,22 ( Suppl 2) : s91-94.
  • 5Parfitt AM. The actions of parathyroid hormone on bone : relation to bone remodeling and turnover, calcium homeostasis, and metabolic bone disease. Part Ⅳ of Ⅳ parts : The state of the bones in uremic hyperparathyroidiam-the mechanisms of skeletal resistance to PTH in renal failure and pseudohypoparathyroidism and the role of PTH in osteoporosis, osteopetrosis, and osteofluorosis. Metabolism, 1976,25 : 1157 -1188.
  • 6Dei Valle E, Negri AL, Aguirre C, Fradingcr E, et al. Prevalence of 25 (OH) vitamin D insufficiency and deficiency in chronic kidney disease stage 5 patients on hemodialysis. Hemodial Int,2007,11:315-321.
  • 7Shigematsu T, Kazama JJ, Yamashita T, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis ,2004,44:250-256.
  • 8Saito H, Kusano K, Kinosaki M, et al. Human fibroblast growth factor 23 reduces expression of type Ⅱa Na +/Pi co-transport activity and 1 alpha, 25-dihydroxyvitamin D3 production. J Biol Chem, 2003, 278 :2206-2211.
  • 9Larsson T, Nisbeth U, Ljunggren O. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int,2003,64:2272-2279.
  • 10Quarles LD, Sherrard D J, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc nephrol,2003 ,14 :575-583.

共引文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部